Reproductive Disorders
AMENORRHEA
Amenorrhea is the abnormal absence of menstruation. Absence of menstruation is normal before puberty, after menopause, or during pregnancy and lactation; it’s pathologic at any other time. Primary amenorrhea is the absence of menarche in an adolescent by age 14 without the development of secondary sex characteristics or by age 16 with normal development of secondary sex characteristics. Secondary amenorrhea is the absence of menstruation for at least 6 months after the normal onset of menarche. Primary amenorrhea occurs in 0.3% of women; secondary amenorrhea occurs in about 4% of women. Prognosis is variable, depending on the specific cause. In the case of obstructive causes, surgical correction of outflow tract obstruction is usually curative.
Causes
Anovulation due to deficient secretion of:
estrogen
gonadotropins
luteinizing hormone (LH)
follicle-stimulating hormone (FSH).
Lack of ovarian response to gonadotropins
Constant presence of progesterone or other endocrine abnormalities
Endometrial adhesions (Asherman’s syndrome)
Ovarian, adrenal, or pituitary tumor
Emotional disorders — common in patients with depression or anorexia nervosa:
Mild emotional disturbances such as stress tend to distort the ovulatory cycle.
Severe psychic trauma may abruptly change the bleeding pattern or completely suppress one or more full ovulatory cycles.
Malnutrition or intense exercise — suppresses hormonal changes initiated by the hypothalamus
Pregnancy
Excessive weight loss
Thyroid disorder
Obesity or excessive weight gain
Ovarian or adrenal tumor
Anatomic defects
Pathophysiology
The mechanism varies depending on the cause and whether the defect is structural, hormonal, or both. Women who have adequate estrogen levels but a progesterone deficiency don’t ovulate and are thus infertile. In primary amenorrhea, the hypothalamic-pituitary-ovarian axis is dysfunctional. Because of anatomic defects of the central nervous system, the ovary doesn’t receive the hormonal signals that normally initiate the development of secondary sex characteristics and the beginning of menstruation.
Secondary amenorrhea can result from any of several mechanisms, including:
central — hypogonadotropic, hypoestrogenic anovulation
uterine — such as Asherman’s syndrome, in which severe scarring has replaced functional endometrium
premature ovarian failure.
Signs and Symptoms
Absence of menstruation
Vasomotor flushes
Vaginal atrophy
Hirsutism
Acne (secondary amenorrhea)
Diagnostic Test Results
Physical and pelvic examination and sensitive pregnancy test rule out pregnancy as well as anatomic abnormalities (such as cervical stenosis) that may cause false amenorrhea (cryptomenorrhea), in which menstruation occurs without external bleeding.
Onset of menstruation (spotting) within 1 week after giving pure progestational agents such as medroxyprogesterone (Provera) indicates enough estrogen to stimulate the lining of the uterus (if menstruation doesn’t occur, special diagnostic studies such as gonadotropin levels are indicated).
Blood and urine studies show hormonal imbalances, such as elevated pituitary gonadotropin levels, low pituitary gonadotropin levels, and abnormal thyroid levels (without suspicion of premature ovarian failure or central hypogonadotropism, gonadotropin levels aren’t clinically meaningful because they’re released in a pulsatile fashion).
Complete medical workup, including appropriate X-rays, computed tomography scans, or magnetic resonance imaging; laparoscopy; and a biopsy, identifies ovarian, adrenal, and pituitary tumors.
Tests to identify dominant or missing hormones include:
“ferning” of cervical mucus on microscopic examination (an estrogen effect)
LH levels
vaginal cytologic examination
endometrial biopsy
serum progesterone level
serum androgen levels
elevated urinary 17-ketosteroid levels with excessive androgen secretions
plasma FSH level more than 50 International Units/L, depending on the laboratory (suggests primary ovarian failure), or normal or low FSH level (possible hypothalamic or pituitary abnormality, depending on the clinical situation).
Treatment
Appropriate hormone replacement to reestablish menstruation
Treatment of the cause of amenorrhea not related to hormone deficiency — for example, surgery for amenorrhea due to a tumor
Inducing ovulation — for example, with clomiphene citrate in women with intact pituitary gland and amenorrhea secondary to gonadotropin deficiency, polycystic ovarian disease, or excessive weight loss or gain
FSH and human menopausal gonadotropins for women with pituitary disease
Reassurance and emotional support (psychiatric counseling if amenorrhea results from emotional disturbances)
Teaching the patient how to keep an accurate record of her menstrual cycles
BREAST CANCER
Breast cancer is the most common cancer affecting women. It is estimated that one in eight women in the United States will develop breast cancer during her lifetime. Male breast cancer accounts for 1% of all male cancers and less than 1% of all breast cancers. The 5-year survival rate for localized breast cancer is 98% because of early diagnosis and a variety of treatments. Lymph node involvement is the most valuable prognostic predictor. With adjuvant therapy, 70% to 75% of women with negative nodes will survive 10 years or more, compared with 20% to 25% of women with positive nodes.
Causes
High Risk Factors
Family history of breast cancer, particularly first-degree relatives (mother, sister, and/or maternal aunt)
Positive tests for genetic mutations (BRCA1 and BRCA2)
Long menstrual cycles, early menarche, late menopause
Nulliparous or first pregnancy after age 30
History of unilateral breast cancer or ovarian cancer
Exposure to low-level radiation
Low Risk Factors
Pregnancy before age 20, history of multiple pregnancies
Native American or Asian ancestry
Pathophysiology
Breast cancer occurs more commonly in the left breast than the right and more commonly in the outer upper quadrant. Slow-growing breast cancer spreads by way of the lymphatic system and the bloodstream, through the right side of the heart to the lungs, and eventually to the other breast, the chest wall, liver, bone, and brain.
Most breast cancers arise from the ductal epithelium. Tumors of the infiltrating ductal type don’t grow to a large size, but metastasize early (70% of breast cancers).
Breast cancer is classified by histologic appearance and location of the lesion, as follows:
adenocarcinoma — arising from the epithelium
intraductal — within the ducts (includes Paget’s disease)
infiltrating — in parenchymal tissue of the breast
inflammatory (rare) — overlying skin becomes edematous, inflamed, and indurated; reflects rapid tumor growth
lobular carcinoma in situ — involves glandular lobes
medullary or circumscribed — large tumor, rapid growth rate.
The descriptive terms should be coupled with a staging or nodal status classification system. The most commonly used staging system is the TNM (tumor size, nodal involvement, metastatic progress).
Signs and Symptoms
Painless lump or mass in the breast, breast pain
Change in symmetry or size of the breast
Change in skin — thickening, scaly skin around the nipple, dimpling, edema (peau d’orange), ulceration, or temperature
Unusual drainage or discharge
Change in nipple (itching, burning, erosion, or retraction)
Pathologic bone fractures, hypercalcemia
Edema of the arm, axillary node enlargement
Dilated blood vessels visible through the skin of the breast
Bone pain
Diagnostic Test Results
Alkaline phosphatase levels and liver function tests uncover distant metastases.
Hormonal receptor assay determines whether the tumor is estrogen or progesterone dependent.
Mammography reveals a tumor that is too small to palpate.
Ultrasonography distinguishes between a fluid-filled cyst and solid mass.
Chest X-rays pinpoint metastases in the chest.
Scans of the bone, brain, liver, and other organs detect distant metastases.
Fine-needle aspiration and excisional biopsy provide cells for histologic examination may confirm the diagnosis.
Treatment
Surgical
Lumpectomy — in many cases, radiation therapy is combined with this surgery
Lumpectomy and dissection of axillary lymph nodes
Quadrant excision
Simple mastectomy — removes breast but not lymph nodes or pectoral muscles
Modified radical mastectomy — removes breast and axillary lymph nodes
Radical mastectomy (now seldom used) — removes breast, axillary lymph nodes, and pectoralis major and minor muscles
Therapy after tumor mapping
Other Treatments
Reconstructive surgery if no advanced disease
Chemotherapy — adjuvant or primary therapy
Selective estrogen receptor modulators such as tamoxifen
Aromatase inhibitors, such as anastrozole and letrozole
Peripheral stem cell therapy for advanced disease
Primary radiation therapy before or after tumor removal:
effective for small tumors in early stages
helps make inflammatory breast tumors more surgically manageable
also used to prevent or treat local recurrence.
Biotherapy with such drugs as trastuzumab, bevacizumab, and lapatinib
BENIGN BREAST CONDITIONS
Also known as fibrocystic disease of the breast, this disorder of benign changes in breast tissue is usually bilateral.
Although most lesions are benign, some may proliferate and show atypical cellular growth. Fibrocystic change by itself isn’t a precursor to breast cancer, but if atypical hyperplasia is present, the risk for breast carcinoma increases.
Causes
Exact cause unknown
Proposed Causes
Estrogen excess and progesterone deficiency during luteal phase of menstrual cycle
Environmental toxins that inhibit cyclic guanosine monophosphate enzymes:
methylxanthines — caffeine (coffee), theophylline (tea), theobromine (chocolate)
tyramine — in cheese, wine, nuts
tobacco.
Pathophysiology
Breast tissue appears to respond to hormonal stimulation, although the exact mechanism is unknown. Fibrocystic breast changes involve three types: cystic, fibrous, and epithelial proliferation. Cysts, fluid-filled sacs, are the most common feature and are easily treated. Fibrous tissue increases progressively until menopause and regresses thereafter. Epithelial proliferation diseases include structurally diverse lesions, such as sclerosing adenosis and the lobular and ductal hyperplasias.
Signs and Symptoms
Breast pain due to inflammation and nerve root stimulation (most common symptom), beginning 4 to 7 days into the luteal phase of the menstrual cycle and continuing until the onset of menstruation
Pain in the upper outer quadrant of both breasts (common site)
Palpable lumps that increase in size premenstrually and are freely moveable (about 50% of all menstruating women)
Granular feeling of breasts on palpation
Occasional greenish-brown to black nipple discharge that contains fat, proteins, ductal cells, and erythrocytes (ductal hyperplasia)
Diagnostic Test Results
Ultrasonography distinguishes cystic (fluid-filled) from solid masses.
Tissue biopsy distinguishes benign from malignant changes.
Cytologic analysis of bloody aspirate rules out malignancy.
CERVICAL CANCER
The third most common cancer of the female reproductive system, cervical cancer is classified as either microinvasive or invasive. Precancerous dysplasia, also called cervical intraepithelial carcinoma or cervical carcinoma in situ, is more frequent than invasive cancer and occurs more often in younger women.
Causes
Human papillomavirus (HPV)
Predisposing Factors
Frequent intercourse at a young age (under age 16)
Multiple sexual partners and/or partner with multiple partners
Multiple pregnancies
Sexually transmitted infections
Smoking
Pathophysiology
Preinvasive disease ranges from mild cervical dysplasia, in which the lower third of the epithelium contains abnormal cells, to carcinoma in situ, in which the full thickness of epithelium contains abnormally proliferating cells. Other names for carcinoma in situ include cervical intraepithelial neoplasia and squamous intraepithelial lesion. Preinvasive disease detected early and properly treated is curable in 75% to 90% of cases. If preinvasive disease remains untreated (and depending on the form
in which it appears), it may progress to invasive cervical cancer. In invasive carcinoma, cancer cells penetrate the basement membrane and can spread directly to contiguous pelvic structures or disseminate to distant sites by lymphatic routes.
In almost all cases of cervical cancer (95%), the histologic type is squamous cell carcinoma, which varies from well-differentiated cells to highly anaplastic spindle cells. Only 5% are adenocarcinomas.
Signs and Symptoms
Preinvasive Disease
Often produces no symptoms or other clinically apparent changes
Early Invasive Cervical Cancer
Abnormal vaginal bleeding
Persistent vaginal discharge
Postcoital pain and bleeding
Advanced Disease
Pelvic pain
Vaginal leakage of urine and stool through a fistula
Anorexia, weight loss, and anemia
Diagnostic Test Results
Papanicolaou (Pap) test screens for abnormal cells.
Colposcopy shows the source of the abnormal cells seen on the Pap test.
Cone biopsy is performed if endocervical curettage is positive.
ViraPap test permits examination of the specimen’s deoxyribonucleic acid structure to detect HPV.
Lymphangiography and cystography detect metastasis.
Organ and bone scans show metastasis.
Treatment
Preinvasive Lesions
Loop electrosurgical excision procedure
Cryosurgery
Laser destruction
Conization (with frequent Pap smear follow-up)
Hysterectomy
Invasive Carcinoma
Radical hysterectomy
Radiation therapy (internal, external, or both)
Chemotherapy
Combination of the above procedures
CLINICAL TIP
Normal
Large, surface-type squamous cells
Small, pyknotic nuclei
Mild Dysplasia
Mild increase in nuclear:cytoplasmic ratio
Hyperchromasia
Abnormal chromatin pattern
Severe Dysplasia, Carcinoma in Situ
Basal type cells
Very high nuclear:cytoplasmic ratio
Marked hyperchromasia
Abnormal chromatin
Invasive Carcinoma
Marked pleomorphism
Irregular nuclei
Clumped chromatin
Prominent nucleoli
CRYPTORCHIDISM
Cryptorchidism is a congenital disorder in which one or both testes fail to descend into the scrotum, remaining in the abdomen inguinal canal or at the external ring. Although this condition may be bilateral, it more commonly affects the right testis. True undescended testes remain along the path of normal descent; ectopic testes deviate from that path.
Undescended testes are susceptible to neoplastic changes. The risk of testicular cancer is greater for men with cryptorchidism than for the general male population.
AGE ALERT
Cryptorchidism occurs in 30% of premature male neonates but in only 3% of those born at term. In about 80% of affected infants, the testes descend spontaneously during the first year; in the rest, the testes may descend later. If indicated, surgical therapy is successful in up to 95% of the cases if the infant is treated early enough.
Causes
Primary cause unknown
Possible Causes
Testosterone deficiency resulting in a defect in the hypothalamic-pituitary-gonadal axis, causing failure of gonadal differentiation and gonadal descent
Structural factors impeding gonadal descent, such as ectopic testis or short spermatic cord
Genetic predisposition in a small number of cases; greater incidence of cryptorchidism in infants with neural tube defects
In premature neonates — early gestational age; normal descent of testes into the scrotum is in seventh month of gestation
Pathophysiology
A prevalent but still unsubstantiated theory links undescended testes to the development of the gubernaculum, a fibromuscular band that connects the testes to the scrotal floor and probably helps pull the testes into the scrotum by shortening as the fetus grows. Normally in the male fetus, testosterone stimulates the formation of the gubernaculum. Thus, cryptorchidism may result from inadequate testosterone levels or a defect in the testes or the gubernaculum. Because the undescended testis is maintained at a higher temperature, spermatogenesis is impaired, leading to reduced fertility.
Signs and Symptoms
Unilateral Cryptorchidism
Testis on affected side not palpable in scrotum; scrotum underdeveloped
Enlarged scrotum on unaffected side due to compensatory hypertrophy (occasionally)
Uncorrected Bilateral Cryptorchidism
Infertility after puberty despite normal testosterone levels
Diagnostic Test Results
Physical examination confirms cryptorchidism after sex is determined by these laboratory tests:
Buccal smear (cells from oral mucosa) determines genetic sex (a male sex chromatin pattern).
Blood test of serum gonadotropin level confirms the presence of testes by showing presence of circulating hormone.
Treatment
Orchiopexy to secure the testes in the scrotum and prevent sterility, excessive trauma from abnormal positioning, and harmful psychological effects (usually before age 4 years; optimum age, 1 to 2 years)
Human chorionic gonadotropin (HCG) I.M. to stimulate descent (rarely); ineffective for testes located in the abdomen
ECTOPIC PREGNANCY
An ectopic pregnancy occurs when a fertilized ovum implants outside the uterine cavity, most commonly in the fallopian tube. Prognosis is good with prompt diagnosis, appropriate surgical intervention, and control of bleeding. Few ectopic pregnancies are carried to term; rarely, with abdominal implantation, the fetus survives to term.
In whites, ectopic pregnancy occurs in about 1 of 200 pregnancies. In nonwhites, the incidence is about 1 of 120 pregnancies.
Causes
Endosalpingitis
Diverticula
Tumors pressing against the tube
Previous surgery, such as tubal ligation or resection
Transmigration of the ovum
Congenital defects in reproductive tract
Ectopic endometrial implants in the tubal mucosa
Sexually transmitted tubal infection or history of STIs and/or PID
Intrauterine device
Pathophysiology
In ectopic pregnancy, transport of a blastocyst to the uterus is delayed and the blastocyst implants at another available vascularized site, usually the fallopian tube lining. Normal signs of pregnancy are initially present and uterine enlargement occurs in about 25% of cases. Human chorionic gonadotropin (HCG) hormonal levels are lower than in uterine pregnancies.
Signs and Symptoms
Abdominal tenderness and discomfort
Amenorrhea
Abnormal menses (after fallopian tube implantation)
Slight vaginal bleeding
Unilateral pelvic pain over the mass
If fallopian tube ruptures, sharp lower abdominal pain, possibly radiating to the shoulders and neck
Diagnostic Tests
Blood test reveals abnormally low serum HCG; when repeated in 48 hours, level remains lower than levels found in a normal intrauterine pregnancy.
Real-time ultrasonography shows intrauterine pregnancy, tubal pregnancy, or ovarian cyst.
Culdocentesis shows free blood in the peritoneum.
Laparoscopy reveals pregnancy outside the uterus.
Treatment
Transfusion with whole blood or packed red blood cells
Broad-spectrum I.V. antibiotics
Supplemental iron
Methotrexate
Analgesics
Rho immune globulin if the patient is Rh negative
Laparotomy and salpingectomy if culdocentesis shows blood in the peritoneum; possibly after laparoscopy to remove affected fallopian tube and control bleeding
Microsurgical repair of the fallopian tube for patients who wish to have children
Oophorectomy for ovarian pregnancy
Hysterectomy for interstitial pregnancy
Laparotomy to remove the fetus for abdominal pregnancy
ENDOMETRIAL CANCER
Also known as uterine cancer (cancer of the endometrium), endometrial cancer is the most common gynecologic cancer.
Causes
Primary cause unknown
Predisposing Factors
Anovulation, abnormal uterine bleeding
History of atypical endometrial hyperplasia
Unopposed estrogen stimulation
Nulliparity
Polycystic ovarian syndrome
Familial tendency
Obesity, hypertension, diabetes
Pathophysiology
In most cases, uterine cancer is an adenocarcinoma that metastasizes late, usually from the endometrium to the cervix, ovaries, fallopian tubes, and other peritoneal structures. It may spread to distant organs, such as the lungs and the brain, through the blood or the lymphatic system. Lymph node involvement can also occur. Less common are adenoacanthoma, endometrial stromal sarcoma, lymphosarcoma, mixed mesodermal tumors (including carcinosarcoma), and leiomyosarcoma.
Signs and Symptoms
Uterine enlargement
Persistent and unusual premenopausal bleeding
Any postmenopausal bleeding
Other signs or symptoms, such as pain and weight loss, don’t appear until the cancer is well advanced
Diagnostic Test Results
Endometrial, cervical, or endocervical biopsy confirms the presence of cancer cells.
Fractional dilation and curettage identifies cancer when biopsy is negative.
Cervical biopsies and endocervical curettage pinpoint cervical involvement.
Treatment
Surgery — generally total abdominal hysterectomy, bilateral salpingo-oophorectomy, or possibly omentectomy with or without pelvic or para-aortic lymphadenectomy
Radiation therapy — intracavitary or external (or both):
if tumor is poorly differentiated or histology is unfavorable
if tumor has deeply invaded uterus or spread to extrauterine sites
may be curative in some patients
Hormonal therapy:
synthetic progesterones, such as medroxyprogesterone or megestrol, for recurrent disease
tamoxifen as a second-line treatment; 20% to 40% response rate
Chemotherapy — usually tried when other treatments have failed:
varying combinations of cisplatin, doxorubicin, etoposide, dactinomycin
no evidence that they are curative.
ENDOMETRIOSIS
Endometriosis is the presence of endometrial tissue outside the lining of the uterine cavity, which occurred during fetal development of the woman. Ectopic tissue is generally confined to the pelvic area, usually around the ovaries, uterovesical peritoneum, uterosacral ligaments, and cul-de-sac, but it can appear anywhere in the body.
Active endometriosis may occur at any age, including adolescence. As many as 50% of infertile women may have endometriosis, although the true incidence in both fertile and infertile women remains unknown.
Severe symptoms of endometriosis may have an abrupt onset or may develop over many years. Of women with endometriosis, 30% to 40% become infertile. Endometriosis usually manifests during the menstrual years; after menopause, it tends to subside.
Causes
Primary cause unknown
Suggested Causes (One or More may be True in Different Women)
Retrograde menstruation with implantation at ectopic sites; may not be causative alone; occurs in women with no clinical evidence of endometriosis
Genetic predisposition and depressed immune system
Coelomic metaplasia (metaplasia of mesothelial cells to the endometrial epithelium caused by repeated inflammation)
Lymphatic or hematogenous spread to extraperitoneal sites
Pathophysiology
The ectopic endometrial tissue responds to normal stimulation in the same way as the endometrium, but less predictably. The endometrial cells respond to estrogen and progesterone with proliferation and secretion. During menstruation, the ectopic tissue bleeds as does the endometrium, which causes inflammation of the surrounding tissues. This inflammation causes fibrosis, leading to adhesions that produce pain and infertility.
Signs and Symptoms
Classic symptoms — dysmenorrhea, abnormal uterine bleeding, infertility
Pain — begins 5 to 7 days before menses, peaks, and lasts for 2 to 3 days; severity doesn’t reflect extent of disease
Depending on site of ectopic tissue:
ovaries and oviducts: infertility, profuse menses
ovaries or cul-de-sac: deep-thrust dyspareunia
bladder: suprapubic pain, dysuria, hematuria
large bowel, appendix: abdominal cramps, pain on defecation, constipation, bloody stools
cervix, vagina, perineum: bleeding from endometrial deposits, painful intercourse
Diagnostic Test Results
Laparoscopy or laparotomy reveals multiple tender nodules on uterosacral ligaments or in the rectovaginal septum and ovarian enlargement in the presence of endometrial cysts on the ovaries.
A pelvic ultrasound test detects an endometrial tissue on an ovary.
Empiric trial of gonadotropin-releasing hormone (GnRH) agonist therapy confirms or refutes the impression of endometriosis before resorting to laparoscopy.
Biopsy at the time of laparoscopy may be helpful to confirm the diagnosis.
Treatment
Conservative Therapy for Young Women who Want to Have Children
Androgens such as danazol
Progestins and continuous combined oral contraceptives (pseudopregnancy regimen) to relieve symptoms by causing regression of endometrial tissue
GnRH agonists to induce pseudomenopause (medical oophorectomy), causing remission of the disease (commonly used)
Analgesics
Antigonadotropin drugs
To Rule Out Cancer, When Ovarian Masses Are Present
Laparoscopic removal of endometrial implants
ERECTILE DYSFUNCTION
Erectile dysfunction, or impotence, refers to a male’s inability to attain or maintain penile erection sufficient to complete intercourse. The patient with primary impotence has never achieved a sufficient erection. Secondary impotence is more common but no less disturbing than the primary form, and implies that the patient has succeeded in completing intercourse in the past.
Transient periods of impotence aren’t considered dysfunction and probably occur in half of adult males. The prognosis for erectile dysfunction patients depends on the severity and duration of their impotence and the underlying causes.
Causes
Psychogenic
Personal sexual anxieties that generally involve guilt, fear, depression, or feelings of inadequacy resulting from previous traumatic sexual experience, rejection by parents or peers, exaggerated religious orthodoxy, abnormal motherson intimacy, or homosexual experiences
Disturbed sexual relationship, possibly stemming from differences in sexual preferences between partners, lack of communication, insufficient knowledge of sexual function, or nonsexual personal conflicts
Situational impotence, a temporary condition in response to stress
Organic
Chronic diseases that cause neurologic and vascular impairment, such as cardiopulmonary disease, diabetes, multiple sclerosis, or renal failure
Liver cirrhosis causing increased circulating estrogen due to reduced hepatic inactivation
Spinal cord trauma
Complications of surgery, particularly radical prostatectomy
Drug- or alcohol-induced dysfunction
Genital anomalies or central nervous system defects
Pathophysiology
Upon stimulation, chemicals are released in the brain that cause signals to pass down the spinal cord and outward through special nerves into the penis. These nerves release another chemical (nitric oxide) that causes the smooth muscles of the penis to relax and blood to rush into the erectile bodies, causing erection. Neurologic dysfunction results in lack of the autonomic signal and, in combination with vascular disease, interferes with arteriolar dilation. The blood is shunted around the sacs of the corpus cavernosum into medium-sized veins, which prevents the sacs from filling completely. Also, perfusion of the corpus cavernosum is initially compromised because of partial obstruction of small arteries, leading to loss of erection before ejaculation.
Anxiety or fear can prevent the brain signals from reaching the level required to induce erection. Medical conditions can block the erection arteries or cause scarring of the spongy erection tissue and prevent proper blood flow or trapping of blood and, therefore, limit the erection.